title: Initial therapy of mantle cell lymphoma.
abstract: Mantle cell lymphoma is a well-recognized distinct clinicopathologic subtype of B-cell non-Hodgkin lymphoma. The current World Health Organization (WHO) classification subdivides this entity into aggressive and other variants. The disease has a predilection for older males, and patients typically present at an advanced stage with frequent splenomegaly and extranodal involvement including bone marrow, peripheral blood, gastrointestinal, and occasional central nervous system involvement. Early studies of therapy outcomes in this disease revealed that while response rates where high, relapse was expected after a limited period of time. Prolonged survival was uncommon, with initial median survival rates typically in the 3-4-year range. Those with a high proliferative rate, blastoid morphology, and selected clinical features were recognized as having a worse prognosis. Therapeutic approaches have diverged into aggressive therapies with high response rates and promising progression free survival rates, which may be applied to younger healthy patients, and less aggressive approaches. Aggressive therapies include intensive chemotherapy alone or chemotherapy followed by autologous stem cell transplant, which has been shown to be most effective when applied in first remission. Whether these more intense therapies result in improved survival as compared with less aggressive therapies is not well established. Allogeneic transplant has also been investigated, although high treatment-related mortality and the risk of chronic graft versus host disease and the relatively advanced age of this patient population have tempered enthusiasm for this approach. A number of less aggressive therapies have been shown to produce promising results. Consolidation and maintenance strategies are an active area of investigation. A number of newer agents have shown promising activity in relapsed disease, and are being investigated in the front-line setting. Overall survival rates are improving in this disease, with current studies suggesting a median survival of 5 or more years.
authors.forename: David J
authors.initials: DJ
authors.lastname: Inwards
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Witzig
keywords: chemotherapy; mantle cell lymphoma; stem cell transplant
references.citation: Ann Oncol. 2010 Jan;21(1):133-9
references.pmid: 20019090
references.citation: Leuk Lymphoma. 2011 Mar;52(3):387-93
references.pmid: 21133713
references.citation: J Clin Oncol. 2009 Aug 10;27(23):3822-9
references.pmid: 19581539
references.citation: Ann Oncol. 2006 Sep;17(9):1418-23
references.pmid: 16766582
references.citation: Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42
references.pmid: 20428863
references.citation: Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27
references.pmid: 20399879
references.citation: Cancer. 2008 Jul 1;113(1):108-16
references.pmid: 18470909
references.citation: Haematologica. 2010 Aug;95(8):1350-7
references.pmid: 20220059
references.citation: J Natl Cancer Inst. 2007 May 2;99(9):706-14
references.pmid: 17470738
references.citation: Leuk Lymphoma. 2008 Jun;49(6):1062-73
references.pmid: 18452065
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6101-8
references.pmid: 19917845
references.citation: Br J Haematol. 2010 Oct;151(1):47-53
references.pmid: 20735402
references.citation: Leuk Lymphoma. 2010 Mar;51(3):406-14
references.pmid: 20038221
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7013-23
references.pmid: 16145068
references.citation: J Clin Oncol. 2009 Feb 1;27(4):511-8
references.pmid: 19075279
references.citation: Br J Haematol. 2002 Sep;118(4):952-8
references.pmid: 12199772
references.citation: Biol Blood Marrow Transplant. 2005 Jan;11(1):39-46
references.pmid: 15625543
references.citation: Blood. 2008 Jan 15;111(2):558-65
references.pmid: 17962512
references.citation: Blood. 2006 Dec 15;108(13):4003-8
references.pmid: 16946304
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5347-56
references.pmid: 15983389
references.citation: Eur J Cancer. 2002 Sep;38(13):1739-46
references.pmid: 12175690
references.citation: Ann Oncol. 2003 Oct;14(10):1555-61
references.pmid: 14504058
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4867-74
references.pmid: 17001068
references.citation: Blood. 2008 Oct 1;112(7):2687-93
references.pmid: 18625886
references.citation: Blood. 2010 Feb 25;115(8):1530-3
references.pmid: 20032504
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1288-94
references.pmid: 11870171
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1209-13
references.pmid: 19188674
references.citation: Hematol Oncol. 1989 Sep-Oct;7(5):365-80
references.pmid: 2670728
references.citation: Cancer. 2008 Aug 1;113(3):508-14
references.pmid: 18543327
references.citation: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003805
references.pmid: 17943799
references.citation: Leuk Lymphoma. 2009 Mar;50(3):463-5
references.pmid: 19197732
references.citation: Cancer. 2010 Jun 1;116(11):2655-64
references.pmid: 20235190
references.citation: Br J Haematol. 2009 Feb;144(4):524-30
references.pmid: 19036081
references.citation: J Clin Oncol. 2010 Jan 20;28(3):418-23
references.pmid: 20008633
references.citation: Leuk Lymphoma. 2001 Nov-Dec;42(6):1235-41
references.pmid: 11911404
references.citation: Cancer Res. 2010 Feb 15;70(4):1408-18
references.pmid: 20124476
references.citation: Leuk Lymphoma. 1999 Sep;35(1-2):129-38
references.pmid: 10512170
references.citation: Blood. 2009 Apr 30;113(18):4144-52
references.pmid: 19168784
references.citation: Bone Marrow Transplant. 2008 Oct;42(8):529-34
references.pmid: 18622414
references.citation: Ann Oncol. 2007 Jan;18(1):116-121
references.pmid: 16971665
references.citation: Blood. 2010 Apr 22;115(16):3215-23
references.pmid: 20032498
references.citation: Ann Oncol. 2005 Apr;16(4):618-24
references.pmid: 15781489
references.citation: Blood. 2005 Apr 1;105(7):2677-84
references.pmid: 15591112
references.citation: Cancer. 2011 May 1;117(9):1901-10
references.pmid: 21509767
references.citation: Br J Haematol. 2010 Jul;150(2):200-8
references.pmid: 20528872
references.citation: Biol Blood Marrow Transplant. 2006 Dec;12(12):1270-6
references.pmid: 17162208
references.citation: Ann Oncol. 2009 Mar;20(3):520-5
references.pmid: 19074748
references.citation: Blood. 2003 Jul 15;102(2):749-55
references.pmid: 12663455
references.citation: Lancet Oncol. 2011 Apr;12(4):361-8
references.pmid: 21440503
references.citation: Cancer. 2005 Oct 1;104(7):1434-41
references.pmid: 16104036
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1984-92
references.pmid: 15668467
references.citation: Br J Haematol. 2009 May;145(3):344-9
references.pmid: 19245430
references.citation: Blood. 2008 Jan 15;111(2):800-5
references.pmid: 17934069
references.citation: Cancer. 2009 Oct 15;115(20):4727-36
references.pmid: 19708031
references.citation: Nucl Med Commun. 2009 Oct;30(10):770-8
references.pmid: 19657307
references.citation: J Clin Oncol. 2011 Feb 20;29(6):690-7
references.pmid: 21189393
references.citation: Ann Oncol. 2011 Jul;22(7):1622-1627
references.pmid: 21228334
references.citation: Blood. 2004 Nov 15;104(10):3064-71
references.pmid: 15284112
references.citation: Br J Haematol. 2008 Feb;140(4):385-93
references.pmid: 18162124
references.citation: Cancer. 2006 Sep 1;107(5):1014-22
references.pmid: 16878325